Nu Skin Enterprises to Present at Bank of America 2008 Consumer ... ( PROVO Utah March 6 /- Nu Skin Ent...)

Nu Skin Enterprises to Present at Bank of America 2008 Consumer Conference

Date:3/6/2008

PROVO, Utah, March 6 /PRNewswire-FirstCall/ -- Nu Skin Enterprises, Inc. (NYSE: NUS) chief financial officer, Ritch Wood, will present at the Bank of America Consumer Conference in New York City on Wednesday, March 12, 2008.

The company's presentation will be webcast live beginning at 2:30 p.m. (EDT). Those wishing to access this presentation can visit the Investor Relations page on Nu Skin Enterprises' Web site, at http://www.nuskinenterprises.com. The archive of the webcast will be available at this same URL through Friday, March 28, 2008.

The Company

Nu Skin Enterprises, Inc. is a global direct selling company operating in more than 45 markets throughout Asia, the Americas and Europe. The company markets premium quality personal care products under the Nu Skin(R) brand, science-based nutritional supplements under the Pharmanex(R) brand, and technology and telecommunications products and services under the Big Planet(R) brand. Nu Skin Enterprises is traded on the New York Stock Exchange under the symbol "NUS."

Nu Skin Enterprises' news releases are available online at http://www.nuskinenterprises.com.

SOURCE Nu Skin Enterprises, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:1/8/2009)...y could shape new treatments for secondary pneumon...swire/ -- Scientists at St. Jude Children,s Resear...atment for bacterial pneumonia following influenza...azithromycin, which kill bacteria by inhibiting th...tandard first-line treatment with the "beta-lactam...

(Date:1/8/2009)... hurtful comments, study suggests , , T...erestimate how strongly they would react to racist...e percent of study participants at York University...ment with a white person rather than a black one, ...bout the black person when he left the room. ,...

(Date:1/8/2009)...ldren,s Research Hospital have demonstrated a more...wing influenza. They found that the antibiotics cl... inhibiting their protein synthesis, are more effe...e "beta-lactam" antibiotic ampicillin, which cause...g is important because pneumonia, rather than the ...

(Date:1/8/2009)...PRNewswire-FirstCall/ -- Hanger Orthopedic Group, ...roughout the fourth quarter of 2008 it acquired Ma...ountain Orthotic-Prosthetics Center, Riessen,s Ort... Orthotics & Prosthetics, and Orthopedic Rehab...tient care centers to existing markets in Maine, L...

Breaking Medicine News(10 mins):Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 2 Health News:Study Finds More Effective Treatment for Pneumonia Following Influenza 3 Health News:Many Turn Blind Eye to Racism 2 Health News:Study finds more effective treatment for pneumonia following influenza 2 Health News:Study finds more effective treatment for pneumonia following influenza 3 Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2

[0] Study Finds More Effective Treatment for Pneumonia Following Influenza [0] Many Turn Blind Eye to Racism [1] Study finds more effective treatment for pneumonia following influenza [0] Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue

...apeutic regimens are effective in suppressing HIV ... treatment may be complicated by development of dr...e // continued concerns over the safety of interru...clinical practice interrupt therapy for reasons re...

... reported at a seniors' home in Toronto and expert... caused the death of four residents at the home. I...here was // no cause to fear an outbreak and stres...e, "This isn't a pandemic by any means, but there ...

...arch in the areas of fetal imaging focus on modali...t women, their unborn babies and newborns with MR ...les diagnosis and treatment of many // disorders t...elayed intervention.. Fetal MRI is usually perform...

...rized by insulin resistance and/or abnormal insuli...inues to expand unabated throughout the world. The...to decreased physical activity, decreased function..., preexisting glucose and insulin abnormalities, a...

Other Medicine News:Health News:Cigarette Smoking Leads To Development Of Type 2 Diabetes In Patients With Coronary Artery Disease 2

HIV treatment interruption may enhance the risk of brain injury Mysterious viral outbreak in Toronto, influenza ruled out Using Eyes As The Line Of Reference For Fetal Brain Imaging Cigarette Smoking Leads To Development Of Type 2 Diabetes In Patients With Coronary Artery Disease

(Date:1/8/2009)...O, Jan. 8 If you are taking prescr...re not alone. Half of the people taking,prescript...ons are,varied -- they forget, are busy with othe.... Noncompliance has been called the Achilles heel ...verett Koop commented, "Drugs don,t,work in peopl...

(Date:1/8/2009)...reated at the initial dose in an ongoing Phase Ib ...ecline after three days , , Conference Call Tod...wire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (N...irst cohort of an ongoing Phase Ib clinical trial ...oside polymerase inhibitor. ANA598 was very well-...

(Date:1/7/2009)...enn., Jan. 7 Scientists...a high likelihood of relapse in children with acut...rchers caution that further research is needed to ...or IKAROS, lead to leukemia relapse, the finding...ostic tests to assess the risk of treatment failur...

(Date:1/7/2009)... Md., Jan. 7 ImQuest Life Sciences...ND application to the Food and Drug Administration...pyrimidinedione HIV inhibitor IQP-0410. ImQuest an...first quarter of 2009. IQP-0410 is a novel small m... nonnucleoside reverse transcriptase inhibitor (NN...

Breaking Medicine Technology:Good Medicine: Smarter Smartphones for People With Chronic Disease 2 ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2 ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3 ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4 ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5 ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6 Gene Abnormality Found to Predict Childhood Leukemia Relapse 2 Gene Abnormality Found to Predict Childhood Leukemia Relapse 3 Gene Abnormality Found to Predict Childhood Leukemia Relapse 4 Gene Abnormality Found to Predict Childhood Leukemia Relapse 5 Gene Abnormality Found to Predict Childhood Leukemia Relapse 6 ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2 Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 1 Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 2 Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 3 Baxter Announces FDA Approval of GELFOAM 28R 29 Plus Hemostasis Kit 2253 4 Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 1 Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 2 Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 3 Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 4 Angiotech Submits 510 28K 29 To FDA For Its Innovative 5 FU CVC 2251 5 WallSt net Announces Upcoming Interview With CEO of ReBuilder Medical Technologies 2249 1 WallSt net Announces Upcoming Interview With CEO of ReBuilder Medical Technologies 2249 2 LeMaitre Vascular Appoints Russell D Hays to Its Board of Directors 2247 1 LeMaitre Vascular Appoints Russell D Hays to Its Board of Directors 2247 2

[0] Good Medicine: Smarter Smartphones for People With Chronic Disease [0] ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients [1] Gene Abnormality Found to Predict Childhood Leukemia Relapse [0] ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410

...oved by FDA for long-term,maintenance treatment of...nebulized formoterol fumarate provides improved lu...nhanced patient quality of,life, and positive safe...ta presented at the,International Conference of th... Perforomist™ (formoterol fumarate),Inhalati...

...The U.S. Food and Drug Administration,(FDA) is awa...(rosiglitazone), a drug approved to treat type 2 d...ls have shown that there is a,potentially signific...-related deaths in patients taking Avandia. Howeve...term clinical trials of,Avandia, including an inte...

Other Medicine Technology:Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2 Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3 Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4 Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5 Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6 Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7 FDA Issues Safety Alert on Avandia 2 FDA Issues Safety Alert on Avandia 3

Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference FDA Issues Safety Alert on Avandia

Durable ergonomic chairs with concave seats and large backrests with lumbar support • Select options like seats, backrests, armrests, and casters and glides. • Choose the BE Series for top

Medicine Products:

BEC/1Q-ERB - Cast Aluminum Base - Model 1Q43-ERB BEC/1Q-ERB - Cast Aluminum Base - Model 1Q72-ERB BEC/1Q-ERB - Cast Aluminum Base - Model 1Q70-ERB BET/1P-ERB - Tubular Base - Model 1P61-ERB

Nu Skin Enterprises to Present at Bank of America 2008 Consumer ...( PROVO Utah March 6 /- Nu Skin Ent...),Health